Cargando…

Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists

Detalles Bibliográficos
Autores principales:	Khani, Elnaz, Entezari-Maleki, Taher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985056/ https://www.ncbi.nlm.nih.gov/pubmed/35388182 http://dx.doi.org/10.1038/s41380-022-01545-3

Ejemplares similares

Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Sigma-1 Receptor Agonist Fluvoxamine Ameliorates Fibrotic Response of Trabecular Meshwork Cells
por: Hodrea, Judit, et al.
Publicado: (2023)

Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors
por: Furuse, Tsutomu, et al.
Publicado: (2009)

A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
por: Albayrak, Yakup, et al.
Publicado: (2019)

A commentary on “Unexpected sudden rise of human monkeypox cases in multiple non-endemic countries amid COVID-19 pandemic and salient counteracting strategies: Another potential global threat?” (Int J Surg 2022;103:106705)
por: Khani, Elnaz, et al.
Publicado: (2022)

Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor
por: Omi, T, et al.
Publicado: (2014)

Commentary on ‘Implications of the SARS-CoV-2 subvariants BA.4 and BA.5’
por: Khani, Elnaz, et al.
Publicado: (2023)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors
por: Furuse, Tsutomu, et al.
Publicado: (2010)

PT576. Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor.
por: Kudo, Takashi
Publicado: (2016)

Enoxaparin’s potential mechanisms against SARS-CoV-2
por: Afsharirad, Bentelhoda, et al.
Publicado: (2023)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review
por: Khani, Elnaz, et al.
Publicado: (2021)

Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases
por: Albayrak, Yakup, et al.
Publicado: (2013)

Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
por: Khiali, Sajad, et al.
Publicado: (2022)

Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Seo, Hyeonji, et al.
Publicado: (2022)

Why we should not recommend or offer fluvoxamine to COVID-19 patients?
por: Trkulja, Vladimir
Publicado: (2022)

Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe
por: Boretti, Alberto
Publicado: (2023)

Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth by Fluvoxamine: Role of Sigma-1 Receptors, IP(3) Receptors and Cellular Signaling Pathways
por: Nishimura, Tomoko, et al.
Publicado: (2008)

Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19
por: Hooper, Philip L.
Publicado: (2021)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Reissuing the sigma receptors for SARS-CoV-2
por: Yesilkaya, Umit Haluk, et al.
Publicado: (2020)

Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism
por: Papadopoulos, Konstantinos, et al.
Publicado: (2023)

Structures of adenosine receptor A(2B)R bound to endogenous and synthetic agonists
por: Cai, Hongmin, et al.
Publicado: (2022)

Overview of the potential use of fluvoxamine for COVID-19 and long COVID
por: Hashimoto, Kenji
Publicado: (2023)

Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Old drug fluvoxamine, new hope for COVID-19
por: Hashimoto, Yaeko, et al.
Publicado: (2021)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis
por: Aghbash, Parisa Shiri, et al.
Publicado: (2021)

Sigma-1 Receptor Agonists Directly Inhibit Na(V)1.2/1.4 Channels
por: Gao, Xiao-Fei, et al.
Publicado: (2012)

Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes
por: Watchorn, David, et al.
Publicado: (2021)

In Reply to ‘Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?’
por: Leehey, David J.
Publicado: (2021)

Anticoagulation in COVID-19: DDI Perspective
por: Khiali, Sajad, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s4jqrsl30eoko0ktq3fhi6bli6